Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.
Rubie H, Geoerger B, Frappaz D, Schmitt A, Leblond P, Ndiaye A, Aerts I, Le Deley MC, Gentet JC, Paci A, Chastagner P, Dias N, Djafari L, Pasquet M, Chatelut E, Landman-Parker J, Corradini N, Vassal G. Rubie H, et al. Among authors: paci a. Eur J Cancer. 2010 Oct;46(15):2763-70. doi: 10.1016/j.ejca.2010.05.004. Epub 2010 Jun 16. Eur J Cancer. 2010. PMID: 20558056 Clinical Trial.
Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
Paci A, Vassal G, Moshous D, Dalle JH, Bleyzac N, Neven B, Galambrun C, Kemmel V, Abdi ZD, Broutin S, Pétain A, Nguyen L. Paci A, et al. Ther Drug Monit. 2012 Apr;34(2):198-208. doi: 10.1097/FTD.0b013e31824c2f60. Ther Drug Monit. 2012. PMID: 22406655
Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma--a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE).
Minard-Colin V, Ichante JL, Nguyen L, Paci A, Orbach D, Bergeron C, Defachelles AS, André N, Corradini N, Schmitt C, Tabone MD, Blouin P, Sirvent N, Goma G, Geoerger B, Oberlin O. Minard-Colin V, et al. Among authors: paci a. Eur J Cancer. 2012 Oct;48(15):2409-16. doi: 10.1016/j.ejca.2012.04.012. Epub 2012 May 25. Eur J Cancer. 2012. PMID: 22633624 Clinical Trial.
Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.
Veal GJ, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D, Brock P, Ladenstein R, Vassal G. Veal GJ, et al. Among authors: paci a. Eur J Cancer. 2012 Nov;48(16):3063-72. doi: 10.1016/j.ejca.2012.05.020. Epub 2012 Jun 26. Eur J Cancer. 2012. PMID: 22742881 Clinical Trial.
Therapeutic drug monitoring in cancer--are we missing a trick?
Bardin C, Veal G, Paci A, Chatelut E, Astier A, Levêque D, Widmer N, Beijnen J. Bardin C, et al. Among authors: paci a. Eur J Cancer. 2014 Aug;50(12):2005-9. doi: 10.1016/j.ejca.2014.04.013. Epub 2014 May 27. Eur J Cancer. 2014. PMID: 24878063
321 results